Cartesian Therapeutics (RNAC) Non Operating Income (2016 - 2025)
Historic Non Operating Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Q2 2025 value amounting to -$5000.0.
- Cartesian Therapeutics' Non Operating Income fell 10171.23% to -$5000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$449000.0, marking a year-over-year decrease of 14544.53%. This contributed to the annual value of $606000.0 for FY2024, which is 1230.1% down from last year.
- Per Cartesian Therapeutics' latest filing, its Non Operating Income stood at -$5000.0 for Q2 2025, which was down 10171.23% from -$444000.0 recorded in Q4 2024.
- Cartesian Therapeutics' Non Operating Income's 5-year high stood at $508000.0 during Q1 2024, with a 5-year trough of -$444000.0 in Q4 2024.
- In the last 5 years, Cartesian Therapeutics' Non Operating Income had a median value of $164500.0 in 2022 and averaged $116928.6.
- Its Non Operating Income has fluctuated over the past 5 years, first soared by 2520000.0% in 2023, then plummeted by 61612.9% in 2024.
- Quarter analysis of 5 years shows Cartesian Therapeutics' Non Operating Income stood at $9000.0 in 2021, then surged by 1844.44% to $175000.0 in 2022, then tumbled by 135.43% to -$62000.0 in 2023, then tumbled by 616.13% to -$444000.0 in 2024, then surged by 98.87% to -$5000.0 in 2025.
- Its last three reported values are -$5000.0 in Q2 2025, -$444000.0 for Q4 2024, and $250000.0 during Q3 2024.